We use cookies to ensure that we give you the best experience on our website Learn more

May 27, 2019

PTCOG58

08 - Proton partial breast irradiation preferentially spares the heart and lungs over modern whole breast radiotherapy

;

proton partial breast irradiation

accelerated partial breast irradiation

3D whole breast irradiation

dosimetric comparison

dosimetry

Abstract

Abstract

thumbnail

Keywords

proton partial breast irradiation

accelerated partial breast irradiation

3D whole breast irradiation

dosimetric comparison

dosimetry

Abstract

Purpose: To compare target coverage and normal tissue sparing of state of the art photon whole breast irradiation (WBI) and proton partial breast irradiation (PPBI). Methods: Consecutive women with node negative breast cancer treated with lumpectomy and adjuvant WBI, without regional nodal irradiation, or PPBI were included. WBI was delivered with 3-dimensional conformal tangential fields, targeting the breast CTV with a 5 mm expansion to PTV to a median dose of 40.05 Gy in 15 fractions. Left-sided WBI patients were treated in deep-inspiratory breath hold. PPBI was delivered with a median of 2 multi-field optimized beams, targeting the lumpectomy cavity plus 1 cm, to a median dose of 21.9 Gy in 3 daily fractions. Setup uncertainty analyses of +/- 3 mm isocenter shifts in each translational axis and 3% beam range uncertainty were performed to ensure robust target coverage and normal tissue sparing. Dosimetric parameters, collected prospectively, are primarily presented as % prescription and we excluded the boost component of WBI for uniformity of plan comparisons. Results: 836 women were treated between 2015-2018; 762 received WBI (274 [36%] with boost to the lumpectomy cavity), and 74 with PPBI. Patients treated with PPBI were older and had more favorable breast cancer (Table 1). Patients treated with PPBI had comparable target coverage but significantly lower heart and lung doses (Table 2). Conclusions: PPBI reduces exposure to the heart and lungs. Follow-up is needed to determine if these dosimetric advantages translate into improved clinical outcomes.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.